Viewing Study NCT00002235


Ignite Creation Date: 2025-12-24 @ 10:23 PM
Ignite Modification Date: 2025-12-31 @ 1:00 AM
Study NCT ID: NCT00002235
Status: COMPLETED
Last Update Posted: 2005-06-24
First Post: 1999-11-02
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Study on the Safety and Effectiveness of Twice-Daily Nelfinavir Plus Twice-Daily Indinavir Plus Efavirenz in HIV-Positive Patients Who Have Never Taken Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) or Protease Inhibitors
Sponsor: Merck Sharp & Dohme LLC
Organization:

Organization Data

Organization:
Class: INDUSTRY
Study ID: 259G
Study Type: None
Study Domain: None
Study Link: None
Lead Sponsor:
Lead Sponsor Class: INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type: None
Responsible Party Affiliation:
Old Name: None
Old Organization: None

Collaborators

Collaborators

Name Class View
None INDUSTRY View